« Previous
Next »
Titles
- Biologics in perspective: the case for generic biologic drugs1
- Cost savings1
- Drug discount program: update on agency efforts to improve 340B program oversight : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives1
- Drug price moderation in Germany: lessons for U.S. reform efforts1
- Indication-specific pricing of pharmaceuticals in the United States health care system: a report from the 2015 ICER Membership Policy Summit1
- Medicare Part B drug payments: impact of price substitutions based on 2017 average sales prices1
- Medicare Part D1
- One percent of drugs with Medicaid reimbursement were not FDA-approved1
- Prescription Drug User Fee Act waivers, reductions, and refunds for drug and biological products1
- Prior authorization requirements for proprotein convertase subtilisin/kexin type 9 inhibitors across US private and public payers1
- Snapshots of recent state initiatives in Medicaid prescription drug cost control1
- The Medicaid Drug Rebate Program: the basics1
- The effect of Medicare Part D on evergreening, generic entry, and drug prices1
- The prescription drug safety net: access to pharmaceuticals for the uninsured1
- What's the latest on Medicare drug price negotiations?1